Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP080
MIFTS: 51

Hypogonadism

Categories: Endocrine diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hypogonadism

About this section

MalaCards integrated aliases for Hypogonadism:

Name: Hypogonadism 11 75 28 53 5 43 14 71

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:1924
MeSH 43 D007006
NCIt 49 C9227
SNOMED-CT 68 48130008
UMLS 71 C0020619
Sources

Summaries for Hypogonadism

About this section

Disease Ontology: 11 A gonadal disease that is characterized by diminished functional activity of the gonads.

MalaCards based summary: Hypogonadism is related to hypogonadotropic hypogonadism 1 with or without anosmia and hypogonadotropic hypogonadism 7 with or without anosmia. An important gene associated with Hypogonadism is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Liraglutide and Dihydrotachysterol have been mentioned in the context of this disorder. Affiliated tissues include testes, pituitary and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased caspase 3/7 activity

Wikipedia: 75 Hypogonadism means diminished functional activity of the gonads—the testes or the ovaries—that may... more...
Sources

Related Diseases for Hypogonadism

About this section

Diseases related to Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1125)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 1 with or without anosmia 33.0 FGFR1 ANOS1
2 hypogonadotropic hypogonadism 7 with or without anosmia 33.0 SPRY4 GNRHR GNRH1 FGFR1 FGF17 DUSP6
3 hypogonadotropic hypogonadism 2 with or without anosmia 32.9 GNRH1 FGFR1 ANOS1
4 hypogonadotropic hypogonadism 23 with or without anosmia 32.8 NSMF LHB GNRHR GNRH1 ANOS1
5 hypogonadism, male 32.7 LHCGR LHB LEP
6 adrenal hypoplasia, congenital 32.7 NSMF NR0B1 GNRH1
7 leydig cell hypoplasia 32.3 LHCGR KISS1R GNRHR GNRH1
8 hypopituitarism 32.2 PROP1 LEP GNRH1 FSHB
9 premature menopause 32.0 TAC3 NR0B1 LHCGR LEP KISS1R KISS1
10 leptin deficiency or dysfunction 32.0 PCSK1 LEP KISS1 GNRH1
11 aromatase excess syndrome 31.9 LEP GNRH1 AR
12 hypogonadotropic hypogonadism 31.7 TAC3 SPRY4 PROP1 NSMF NR0B1 NDNF
13 normosmic congenital hypogonadotropic hypogonadism 31.7 TAC3 SPRY4 NSMF KISS1R KISS1 GNRHR
14 kallmann syndrome 31.7 TAC3 SPRY4 PROP1 PCSK1 NSMF NR0B1
15 charge syndrome 31.7 TAC3 NSMF KISS1R GNRHR GNRH1 FGFR1
16 prader-willi syndrome 31.6 PCSK1 LEP GNRH1 AR
17 46,xy sex reversal 31.3 PROP1 NSMF NR0B1 LHCGR GNRHR GNRH1
18 gynecomastia 31.3 LEP GNRH1 AR
19 amenorrhea 31.2 LHCGR LHB LEP GNRHR GNRH1 FSHB
20 penis agenesis 31.2 LHCGR GNRH1 AR ANOS1
21 infertility 31.1 TAC3 LHCGR LHB LEP GNRHR GNRH1
22 azoospermia 31.1 NR0B1 KISS1R GNRH1 FSHB AR
23 turner syndrome 31.1 NR0B1 LEP AR
24 male infertility 31.0 LHB GNRH1 FGFR1 AR ANOS1
25 precocious puberty 30.9 LHCGR KISS1R GNRH1
26 testicular disease 30.9 SPRY4 LHCGR GNRH1 AR
27 coloboma of macula 30.8 GNRHR GNRH1 FGFR1 ANOS1
28 varicocele 30.7 LEP GNRH1 AR
29 cryptorchidism, unilateral or bilateral 30.7 TAC3 SPRY4 PROP1 NSMF NR0B1 LHCGR
30 oligospermia 30.7 GNRHR GNRH1 AR
31 polycystic ovary syndrome 30.6 LHCGR LEP GNRH1 FSHB AR
32 sexual health disorder 30.6 GNRH1 AR
33 renal hypodysplasia/aplasia 1 30.6 TAC3 NSMF GNRHR GNRH1 FGFR1 ANOS1
34 conn's syndrome 30.5 NR0B1 LHCGR LEP GNRHR GNRH1
35 anovulation 30.5 LHCGR LEP KISS1 GNRH1 FSHB
36 ovarian hyperstimulation syndrome 30.4 LHCGR GNRH1 FSHB
37 empty sella syndrome 30.4 PROP1 GNRH1
38 ovarian disease 30.4 LHCGR LEP KISS1 GNRH1 AR
39 choanal atresia, posterior 30.4 NSMF GNRHR FGFR1 ANOS1
40 pseudohermaphroditism 30.4 NR0B1 LHCGR LHB GNRHR GNRH1 AR
41 lipoid congenital adrenal hyperplasia 30.3 NR0B1 LHCGR LEP KISS1 GNRH1 AR
42 pituitary stalk interruption syndrome 30.3 NSMF KISS1R
43 testicular germ cell cancer 30.2 SPRY4 LHCGR AR
44 central precocious puberty 30.1 TAC3 NR0B1 LEP KISS1R KISS1 GNRHR
45 precocious puberty, male-limited 30.1 LHCGR KISS1R KISS1 GNRHR GNRH1
46 gender incongruence 30.1 GNRH1 AR
47 sensorineural hearing loss 30.0 TAC3 SPRY4 NSMF NDNF KISS1R KISS1
48 glucocorticoid deficiency 1 30.0 KISS1R KISS1 GNRHR
49 leydig cell hypoplasia type ii 30.0 LHCGR LHB GNRH1
50 17-beta hydroxysteroid dehydrogenase iii deficiency 30.0 NR0B1 GNRH1 AR

Graphical network of the top 20 diseases related to Hypogonadism:



Diseases related to Hypogonadism
Sources

Symptoms & Phenotypes for Hypogonadism

About this section

GenomeRNAi Phenotypes related to Hypogonadism according to GeneCards Suite gene sharing:

25 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ANOS1 AR DUSP6 FGF17 FGFR1 FSHB
2 no effect GR00402-S-2 10.19 ANOS1 AR DUSP6 FGF17 FGFR1 FSHB
3 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.91 FGFR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.91 LHB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.91 KISS1R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 FGFR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.91 KISS1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.91 FGFR1 KISS1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.91 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.91 LHB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.91 KISS1R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.91 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.91 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 FGFR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.91 KISS1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.91 KISS1R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.91 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.91 LHB
20 Decreased caspase 3/7 activity GR00318-A 9.33 AR LHB LHCGR

MGI Mouse Phenotypes related to Hypogonadism:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AR DUSP6 FGFR1 FSHB GNRH1 GNRHR
2 nervous system MP:0003631 10.25 AR FGF17 FGFR1 GNRH1 GNRHR KISS1
3 growth/size/body region MP:0005378 10.17 AR DUSP6 FGFR1 GNRH1 GNRHR KISS1
4 endocrine/exocrine gland MP:0005379 10.13 AR FGFR1 FSHB GNRH1 GNRHR KISS1
5 renal/urinary system MP:0005367 10.01 AR FGFR1 GNRH1 GNRHR KISS1 KISS1R
6 digestive/alimentary MP:0005381 9.9 AR FGFR1 GNRH1 GNRHR KISS1 KISS1R
7 cellular MP:0005384 9.77 AR DUSP6 FGFR1 FSHB GNRHR KISS1
8 reproductive system MP:0005389 9.5 AR FGFR1 FSHB GNRH1 GNRHR KISS1
Sources

Drugs & Therapeutics for Hypogonadism

About this section

Drugs for Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
2
Dihydrotachysterol Approved Phase 4 67-96-9 5311071
3
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
4
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
5
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
6
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
7
Follitropin Approved, Vet_approved Phase 4 97048-13-0, 146479-72-3, 9002-68-0 62819
8
Nutmeg Approved Phase 4
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
12
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
13
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
14 Estrogen Receptor Antagonists Phase 4
15 Estrogen Antagonists Phase 4
16 Incretins Phase 4
17 Vitamins Phase 4
18 Calciferol Phase 4
19 Contraceptive Agents Phase 4
20
Triptorelin Pamoate Phase 4
21 Insulin, Globin Zinc Phase 4
22
Insulin Phase 4
23 Calcium, Dietary Phase 4
24 Fenugreek seed meal Phase 4
25 Fenugreek Phase 4
26 Trace Elements Phase 4
27 Micronutrients Phase 4
28
Vitamin D2 Phase 4 3249
29 Ergocalciferols Phase 4
30 Aromatase Inhibitors Phase 4
31 Mace Phase 4
32 Pharmaceutical Solutions Phase 4
33 Follicle Stimulating Hormone Phase 4
34 Phosphodiesterase Inhibitors Phase 4
35 Phosphodiesterase 5 Inhibitors Phase 4
36 Vasodilator Agents Phase 4
37 Vardenafil Dihydrochloride Phase 4
38 Estradiol 3-benzoate Phase 4
39 Estradiol 17 beta-cypionate Phase 4
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
42
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
43
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
44
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
45
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4 96919
46
Stanolone Illicit, Investigational Phase 3 521-18-6 10635
47 Estrogens Phase 3
48 Hypoglycemic Agents Phase 3
49 Anticoagulants Phase 3
50 Chelating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 324)
# Name Status NCT ID Phase Drugs
1 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
2 Study on the Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
3 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin is Superior to Human Chorionic Gonadotropin in Therapeutic Efficacy in Adolescent Boys With Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
4 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
5 Effects of Liraglutide and Testosterone Replacement Therapy on Features of Hypogonadism and Weight Loss in Obese Men With Persistent Features of Hypogonadism. Completed NCT03619330 Phase 4 liraglutide;Testosterone
6 Phase 4 Study of Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
7 Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111434 Phase 4 Testosterone
8 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
9 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
10 The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease Completed NCT02433730 Phase 4 Testosterone;placebo
11 Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism Completed NCT01107067 Phase 4 Sustanon
12 Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men Completed NCT01127659 Phase 4 testosterone;placebo
13 Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients With Hypogonadotropic Hypogonadism-Last Three Years Experience Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
14 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Completed NCT00350701 Phase 4 androgel;androgel 10g;placebo
15 Phase 4 Study That Evaluates the Presence of Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism and Effects of Two Different Testosterone Replacement Regiments on These Parameters. Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
16 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
17 Efficacy and Safety of Human Chorionic Gonadotropin (HCG) and Follicle Stimulating Hormone (FSH) in the Treatment of Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
18 Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism. Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
19 A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™) Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
20 A Phase IV, Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of 16 Weeks Treatment With Androderm® in Hypogonadal Men Completed NCT04320745 Phase 4 Androderm®
21 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
22 Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men Completed NCT03091348 Phase 4 Testosterone
23 Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome Completed NCT00487734 Phase 4 Placebo for testosterone gel
24 Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
25 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
26 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
27 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
28 24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy Completed NCT04274894 Phase 4 AndroGel 1.62%
29 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
30 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Completed NCT02959853 Phase 4 Anastrazole
31 A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00504712 Phase 4 Testosterone;saline
32 Testosterone Replacement and Dutasteride Effectiveness (TRADE) Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
33 Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue Completed NCT01123278 Phase 4 Testosterone;Placebo
34 A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin Completed NCT00349362 Phase 4 Testosterone;0.9% saline
35 Effects of Testosterone Replacement on Atherosclerosis Progression in Older Men With Low Testosterone Levels Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
36 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
37 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Completed NCT03203681 Phase 4 Natesto
38 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM. Completed NCT01560546 Phase 4 Testosterone;Placebo
39 A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
40 Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome Completed NCT01160341 Phase 4 Testosteron
41 An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Administration With Marketed Testosterone Products Recruiting NCT04456296 Phase 4 Aveed Injectable Product;Fortesta;Testim
42 A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids on Plasma Reproductive Hormones, Fertility, Withdrawal Symptoms and Myocardial Function - The LUCAS Trial Recruiting NCT05205837 Phase 4 Letrozole 2.5mg, hCG;Placebo
43 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo
44 52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters Recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
45 Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in the Treatment of Male Patients With Isolated Hypogonadotropic Hypogonadism: an Open, Randomized Controlled Study Recruiting NCT03687606 Phase 4 Human Chorionic Gonadotropin;human menopausal gonadotropin
46 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
47 A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of Vogelxo(R) on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy Recruiting NCT04558567 Phase 4 Vogelxo
48 Muscle Strength and -Mass After Bariatric Surgery - a Possible Effect of Testosterone Replacement Therapy? Randomized, Placebo-controlled and Double-blinded Study Recruiting NCT03721497 Phase 4 Testosterone Undecanoate
49 A 24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated With Natesto Nasal Testosterone Gel Recruiting NCT04976595 Phase 4 Natesto
50 Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study Active, not recruiting NCT03518034 Phase 4 Testosterone;Placebo

Search NIH Clinical Center for Hypogonadism

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Black Cohosh Extract
Bromocriptine
Chlorotrianisene
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
estropipate
Ethinyl Estradiol
Ethynodiol Diacetate
Fluoxymesterone
Methyltestosterone
METHYLTESTOSTERONE PWDR
Norethindrone
norethindrone acetate
polyestradiol
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B
Testosterone
testosterone cypionate
testosterone enanthate
Testosterone Propionate
TESTOSTERONE PROPIONATE PWDR
TESTOSTERONE PWDR
testosterone undecanoate

Cochrane evidence based reviews: hypogonadism

Sources

Genetic Tests for Hypogonadism

About this section

Genetic tests related to Hypogonadism:

# Genetic test Affiliating Genes
1 Hypogonadism 28
Sources

Anatomical Context for Hypogonadism

About this section

Organs/tissues related to Hypogonadism:

MalaCards : Testes, Pituitary, Prostate, Bone, Spinal Cord, Bone Marrow, Endothelial
Sources

Publications for Hypogonadism

About this section

Articles related to Hypogonadism:

(show top 50) (show all 11810)
# Title Authors PMID Year
1
Novel insights in FGFR1 regulation: lessons from Kallmann syndrome. 53 62
20117945 2010
2
Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. 53 62
19656574 2010
3
[Case of progressive prostatic carcinoma in a patient with acquired hypogonadism]. 53 62
20448451 2010
4
A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. 53 62
19966036 2010
5
Management of erectile dysfunction. 53 62
20112889 2010
6
Recombinant follitropin alfa/lutropin alfa in fertility treatment. 53 62
20161981 2010
7
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. 53 62
19912506 2010
8
Narrative review: the role of leptin in human physiology: emerging clinical applications. 53 62
20083828 2010
9
Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. 53 62
19226407 2009
10
Prostate cancer and acromegaly. 53 62
20126848 2009
11
Relationship between insulin and hypogonadism in men with metabolic syndrome. 53 62
20126854 2009
12
Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: is there a link? 53 62
19719531 2009
13
Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. 53 62
19523548 2009
14
Dimeric PROP1 binding to diverse palindromic TAAT sequences promotes its transcriptional activity. 53 62
19524124 2009
15
Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. 53 62
19458139 2009
16
The emerging link between hypogonadism and metabolic syndrome. 53 62
18772486 2009
17
Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. 53 62
19344792 2009
18
Bone mineral density and disorders of mineral metabolism in chronic liver disease. 53 62
19630107 2009
19
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. 53 62
19154450 2009
20
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. 53 62
19176467 2009
21
Leptin: a pivotal regulator of human energy homeostasis. 53 62
19211814 2009
22
Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. 53 62
19347183 2009
23
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. 53 62
19156143 2009
24
Has prolactin a role in the hypogonadal status of HIV-infected patients? 53 62
19171915 2009
25
Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women. 53 62
19129711 2009
26
FSHbeta gene mutation in a female with delayed puberty and hypogonadism: response to recombinant human FSH. 53 62
20067895 2009
27
Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. 53 62
18854428 2008
28
Laboratory diagnosis of late-onset male hypogonadism andropause. 53 62
19197450 2008
29
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 53 62
18951767 2008
30
Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. 53 62
18248650 2008
31
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. 53 62
19095599 2008
32
Testosterone and erectile dysfunction. 53 62
18641415 2008
33
Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). 53 62
18429947 2008
34
Acylated ghrelin and leptin in adolescent athletes with amenorrhea, eumenorrheic athletes and controls: a cross-sectional study. 53 62
18331605 2008
35
[Testosterone replacement in hypogonadotropic hypogonadal young male improves insulin sensitivity]. 53 62
19080648 2008
36
Kisspeptin and GPR54: discovery of a novel pathway in reproduction. 53 62
18601695 2008
37
Bone density in the adolescent athlete. 53 62
18409004 2008
38
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. 53 62
18449947 2008
39
Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. 53 62
18195686 2008
40
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. 53 62
18343420 2008
41
Prevalence of androgen deficiency in men with erectile dysfunction. 53 62
18313109 2008
42
[Phenotype of patients with gynecomastia]. 53 62
18465688 2008
43
The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin. 53 62
18283239 2008
44
Seminiferous tubule function in delayed-onset X-linked adrenal hypoplasia congenita associated with incomplete hypogonadotrophic hypogonadism. 53 62
17803711 2008
45
Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. 53 62
18205549 2008
46
Metabolic syndrome and reproduction: I. testicular function. 53 62
18224542 2008
47
Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? 53 62
18447401 2008
48
Cholestasis and metabolic bone disease - a clinical review. 53 62
18998071 2008
49
[Pathogenetically complicated case of osteoporosis in a young man]. 53 62
19097362 2008
50
The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. 53 62
18987492 2008
Sources

Variations for Hypogonadism

About this section

ClinVar genetic disease variations for Hypogonadism:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CKAP2L NM_152515.5(CKAP2L):c.1463_1467del (p.Thr488fs) DEL Likely Pathogenic
 1183968 GRCh37: 2:113509979-113509983
GRCh38: 2:112752402-112752406
2 IL17RD NM_017563.5(IL17RD):c.1371T>G (p.Ile457Met) SNV Uncertain Significance
 1676256 GRCh37: 3:57132360-57132360
GRCh38: 3:57098332-57098332
Sources

Expression for Hypogonadism

About this section
Search GEO for disease gene expression data for Hypogonadism.
Sources

Pathways for Hypogonadism

About this section

Pathways related to Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
GPCR downstream signalling 66
Show member pathways
 13.28 TAC3 LHCGR LHB KISS1R KISS1 GNRHR
2
Signal Transduction 66
13.21 TAC3 LHCGR LHB LEP KISS1R KISS1
3
Class A/1 (Rhodopsin-like receptors) 66
Show member pathways
 12.99 FSHB GNRH1 GNRHR KISS1 KISS1R LHB
4
Beta-2 adrenergic-dependent CFTR expression 22
Show member pathways
 12.33 LHCGR LHB GNRHR FSHB
5
Peptide hormone metabolism 66
Show member pathways
 11.85 PCSK1 LHB LEP FSHB
6
G-protein signaling_RhoA regulation pathway 22
11.42 LHB GNRH1 FGFR1 FGF17
7
Prader-Willi and Angelman syndrome 74
11.32 PCSK1 KISS1 GNRH1
8
Nongenotropic Androgen signaling 61
10.71 GNRH1 AR
9
Kallmann syndrome 74
10.65 LHB FGFR1 ANOS1
10
Hormone ligand-binding receptors 66
10.1 LHCGR LHB GNRHR GNRH1 FSHB
Sources

GO Terms for Hypogonadism

About this section

Cellular components related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.66 TAC3 PCSK1 NDNF LHCGR LHB LEP

Biological processes related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 10.01 LEP KISS1 FGFR1 AR
2 male gonad development GO:0008584 9.86 AR LHB LHCGR NR0B1
3 cell-cell signaling GO:0007267 9.85 PCSK1 LHB GNRH1 FGF17 AR
4 Leydig cell differentiation GO:0033327 9.78 NR0B1 AR
5 cellular response to gonadotropin stimulus GO:0071371 9.67 NSMF LHCGR
6 multicellular organism development GO:0007275 9.63 SPRY4 GNRH1 FGFR1
7 positive regulation of luteinizing hormone secretion GO:0033686 9.62 LEP KISS1
8 regulation of steroid biosynthetic process GO:0050810 9.61 LHCGR LEP
9 progesterone biosynthetic process GO:0006701 9.26 LHB FSHB
10 pituitary gland development GO:0021983 9.02 PROP1 PCSK1 NR0B1

Molecular functions related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 LHB LEP GNRH1 FSHB
2 protein-hormone receptor activity GO:0016500 8.96 LHCGR GNRHR
Sources

Sources for Hypogonadism

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....